Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Institute of Pain Medicine, Rambam Health Care Campus, Haifa, Israel.
Palliat Support Care. 2020 Feb;18(1):12-17. doi: 10.1017/S147895151900021X.
The objectives were to evaluate the, usability, feasibility of use, satisfaction, and safety of the Syqe Inhaler Exo (Syqe Inhaler), a metered dose, Pharmacokinetics-validated, cannabis inhaler device in a cohort of hospitalized patients that were using medical cannabis under license as a part of their ongoing medical treatment.
Before and after inhaling from the Syqe Inhaler, participants were asked to fill a questionnaire regarding pain reduction on a visual analog scale from 0 to 10 and, if relevant, reduction in chemotherapy-induced nausea and vomiting and/or spasticity. A patient satisfaction questionnaire and a usability questionnaire were filled in following the last use. Prescribed treatment included 4 daily doses of 500 μg tetrahydrocannabinol each delivered from 16 mg cannabis flos per inhalation plus up to an additional four SOS (distress code for more doses of cannabis) doses.
Daily cannabis dose consumed during hospitalization with the Syqe Inhaler was 51 mg (20-96) versus 1,000 mg (660-3,300) consumed prehospitalization. Patients were easily trained and continued to use Syqe Inhaler for the duration of their hospitalization (5 [3-7] days). Pain intensity 30-60 minutes following inhalations was reported to be significantly lower than preinhalation 4 [1-5] versus 7 [2-9]). Participants ranked their satisfaction with Syqe Inhaler as 6 (5-7). Three participants reported mild cough, which resolved spontaneously.
Cannabis inhalation by combustion is not feasible for hospitalized patients. The use of Syqe Inhaler during hospitalization yielded high levels of patients and staff satisfaction with no complications.
评估 Syqe 吸入器 Exo（Syqe 吸入器）的可用性、使用可行性、满意度和安全性，该设备为定量吸入器，药代动力学验证，是一种大麻吸入装置，适用于正在使用许可医疗大麻作为其持续治疗一部分的住院患者。
在使用 Syqe 吸入器吸入前后，参与者被要求在视觉模拟量表上从 0 到 10 分评估疼痛减轻程度，如果相关，还评估化疗引起的恶心和呕吐以及/或痉挛的减轻程度。在最后一次使用后填写患者满意度问卷和可用性问卷。规定的治疗包括每天 4 次，每次 500μg 四氢大麻酚，每次从 16mg 大麻花中吸入，并可按需加用 4 次 SOS（更多剂量大麻的紧急代码）。
使用 Syqe 吸入器住院期间每天消耗的大麻剂量为 51mg（20-96），而住院前每天消耗的大麻剂量为 1000mg（660-3300）。患者很容易接受培训，并在住院期间继续使用 Syqe 吸入器（5[3-7]天）。吸入后 30-60 分钟的疼痛强度明显低于吸入前的 4[1-5]分）。参与者对 Syqe 吸入器的满意度评分均为 6（5-7）。有 3 名参与者报告有轻度咳嗽，自行缓解。
住院患者无法进行大麻燃烧吸入。在住院期间使用 Syqe 吸入器产生了高水平的患者和工作人员满意度，没有并发症。
